Clinical significance of high β2 microglobulin in diffuse large B cell lymphoma

ObjectiveTo explore the clinical value of β2 microglobulin in diffuse large B cell lymphoma.

MethodsThe clinical data of 102 patients with diffuse large B cell lymphoma were retrospectively analyzed.The age at first diagnosis, gender, Ann Arbor stage, serum levels of lactate dehydrogenase and hypoglobulin, with and without group B symptoms and ECOG scores of patients were recorded.According to the international prognostic index(IPI) and national comprehensive cancer cefter international prognostic index(NCCN-IPI) scoring criteria, the data of patient were statistically analyzed.

ResultsThe difference of the number of cases with increasing microglobulin level among different groups was statistically significant(P < 0.01).With the increasing of prognostic risk level, the level of β2 microglobulin increased gradually, and the level of β2 microglobulin in high-risk group was significantly higher than that in low-risk group and medium-risk group(P < 0.01).The results of logistic regression analysis showed that the increasing of β2 microglobulin level was a risk factor of IPI and NCCN-IPI prognosis grouping(P < 0.01).The correlation analysis showed that β2 microglobulin was not correlated with lactic dehydrogenase and external node involvement(P>0.05), and β2 microglobulin was correlated with the age, tumor stage and ECOG score(P < 0.05).

ConclusionsThe level increasing of β2 microglobulin may be one of the risk factors of patients with diffuse large B lymphoma, and the related mechanism of which needs to be further studied.